IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
How Smoking Causes COPD: Examination of Immune System Changes
The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2011 by St. Joseph's Healthcare Hamilton.
Recruitment status was: Recruiting
Recruitment status was: Recruiting
Sponsor:
St. Joseph's Healthcare Hamilton
Information provided by:
St. Joseph's Healthcare Hamilton
ClinicalTrials.gov Identifier:
NCT00186719
First received: September 13, 2005
Last updated: July 25, 2011
Last verified: July 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
A breathing condition known as "chronic obstructive pulmonary disease" (COPD) caused by cigarette smoking is a major health problem. The way by which smoking leads to lung disease is uncertain. Recent research done in animals provides a description of specific changes (that is a reduction) in these immune cell types as a result of cigarette smoke exposure. The study you have been asked to participate in is a pilot study to see if similar changes occur in humans who smoke. The purpose of this study is to evaluate this new method of testing blood in 3 groups of 10 people: normal non-smoking subjects, subjects who smoke with no history of lung disease and subjects who smoke and have smoking related COPD.
| Condition |
|---|
| Chronic Obstructive Pulmonary Disease |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | How Smoking Causes COPD: Examination of Immune System Changes |
Resource links provided by NLM:
Further study details as provided by St. Joseph's Healthcare Hamilton:
| Estimated Enrollment: | 100 |
| Study Start Date: | May 2005 |
| Estimated Study Completion Date: | April 2012 |
The mechanism by which smoking leads to damage to lung tissue in susceptible hosts, is uncertain. Recently there has been description of specific changes (that is reduction) in the number and activity of certain key immune cell types - dendritic cells- as a result of cigarette smoke exposure. This work was done in animal models and we would like to develop methods that will allow us to examine if similar changes occur in humans who smoke. Reduced number and activity of dendritic cells would be expected to lead to increased incidence of infection - a common problem in patients with COPD.
Since dendritic cells come to the lung from the bloodstream, and one can detect them in the circulation, we will look at the dendritic cells that are present in the peripheral blood.
Eligibility| Ages Eligible for Study: | 40 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Study Population
smokers and non-smokers
Criteria
Inclusion Criteria:
- Age > 40 years
- Healthy Subjects - Non smokers
- FEV1/FVC > 70% predicted
- Current Smokers - > 10 pack year smoking history
- FEV1/FVC > 70% predicted
- Current Smokers with COPD - > 10 pack year smoking history
- FEV1/FVC < 70% predicted
- Able to give informed consent
Exclusion Criteria:
- Healthy Subjects - Reside with smokers
- History of lung disease
- Current Smokers - History of lung disease
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00186719
Please refer to this study by its ClinicalTrials.gov identifier: NCT00186719
Contacts
| Contact: Susan E Carruthers, MLT | 905-522-1155 ext 2208 | scarruth@stjosham.on.ca | |
| Contact: Sarah E Goodwin, BA RRT CCRC | 905-522-1155 ext 6130 | sgoodwin@stjosham.on.ca |
Locations
| Canada, Ontario | |
| St Joseph's Healthcare | Recruiting |
| Hamilton, Ontario, Canada, L8N 4A6 | |
| Contact: Gerard Cox, MB FRCPC FRCPI 905-522-1155 ext 5039 coxp@mcmaster.ca | |
| Contact: Martin Stampfli, PhD 905-525-9140 ext 22473 stampfli@mcmaster.ca | |
| Principal Investigator: Gerard Cox, MB FRCPC FRCPI | |
| Sub-Investigator: Martin Stampfli, PhD | |
Sponsors and Collaborators
St. Joseph's Healthcare Hamilton
Investigators
| Principal Investigator: | Gerard Cox, MB FRCPC FRCPI | McMaster University |
More Information
| Responsible Party: | Dr. Gerard Cox, St. Joseph's Healthcare Hamilton |
| ClinicalTrials.gov Identifier: | NCT00186719 History of Changes |
| Other Study ID Numbers: |
02-2182 |
| Study First Received: | September 13, 2005 |
| Last Updated: | July 25, 2011 |
Keywords provided by St. Joseph's Healthcare Hamilton:
|
Chronic Obstructive Pulmonary Disease Smoking Related Disease Immune System Changes |
Additional relevant MeSH terms:
|
Lung Diseases Lung Diseases, Obstructive Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on July 21, 2017